|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-5 alone was able to generate significant numbers of eos in TG5 but not FVB mice, whereas a combination of IL-5 and IL-9 induced marked eosinophilia in both strains indicating a synergism between these 2 cytokines.
|
11159534 |
2001 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-5 is a key factor for eosinophilia and could therefore be responsible for some of the tissue damage seen in chronic asthma.
|
11477111 |
2001 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin 5 (IL-5) is a key cytokine in the regulation of eosinophilia and eosinophil activation in humans.
|
15474864 |
2004 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-5 is a major therapeutic target to reduce eosinophilia.
|
26276876 |
2015 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-5 (IL-5) was identified for its role in eosinophil development, maturation, and survival in tissues, which has been related to disease severity and airway eosinophilia.
|
28116937 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-5 induced eosinophilia only, but IL-13 contributed to both nasal epithelial thickening and eosinophilia induced by OVA-plus-papain.
|
28541554 |
2017 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-5 neutralization before allergen challenge abolished the allergen-induced rise in circulating eosinophils and expression of IL-3 receptors, whereas airway eosinophilia and eosinophil peroxidase deposition were blunted but not eliminated.
|
28862877 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-5 is a selective stimulator for the production of eosinophilia and is considered to play an important role in Kimura's disease.
|
9779259 |
1998 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A 64-year-old woman had eosinophilia (14.1 x 10(9)/L) and an anterior mediastinal tumor with elevated levels of serum immunoglobulin E (609.8 mg/dL) and interleukin 5 (239 pg/mL).
|
16720555 |
2006 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A type 2 immune response was associated with exposure, with increased interleukin-4 (IL-4) production, IL-5 transcription, and eosinophilia.
|
28993458 |
2018 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
After epithelial barrier disruption, intranasal OVA application induced higher OVA-specific IgG1 and total IgE in serum, and increased eosinophilia and interleukin-5 in bronchoalveolar lavage (BAL) compared to sham-OVA mice.
|
31769882 |
2019 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All cases expressed the IL-3R but the IL-5R gene was expressed predominantly in leukaemic cells with either t(8;21) or CD4-positive immunophenotype and was associated with the presence of eosinophilia.
|
7577627 |
1995 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Alternative strategies to inhibit eosinophilic inflammation include the use of immunostimulatory DNA sequences containing a CpG motif to act as a Th1 adjuvant to prevent Th2 responses associated with IL-5 and eosinophilia.
|
11292020 |
2001 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
As the causes of persistent eosinophilia in patients with the idiopathic hypereosinophilic syndrome (HES) are (by definition) unknown, a semi-quantitative assay for IL-5 mRNA in eosinophils and mononuclear cells was carried out using samples from 11 patients with HES.
|
7835952 |
1994 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on the data presented, I propose omalizumab for patients with an allergic phenotype regardless of their peripheral eosinophilic count, and anti-IL-5 as an alternative in allergic patients with blood eosinophilia in which omalizumab has failed; anti-IL5 for patients with an eosinophilic phenotype and omalizumab as an alternative in patients in whom anti-IL5 fails and IgE ≥30 IU/mL (compassionate use).
|
28948572 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Blood lymphocytes from patients with eosinophilia are known to produce interleukin-5 (IL-5) with appropriate stimulation in vitro.
|
8092143 |
1994 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia.
|
28921511 |
2018 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
By using mice deficient in both IL-5 and eotaxin (IL-5/eotaxin(-/-)) we have abolished tissue eosinophilia and the induction of AHR in the allergic lung.
|
12045241 |
2002 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined IL-2 Immunocomplex and Anti-IL-5 mAb Treatment Expands Foxp3<sup>+</sup> Treg Cells in the Absence of Eosinophilia and Ameliorates Experimental Colitis.
|
30930900 |
2019 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Conspicuous eosinophilia in early-onset FPIES is suggested to be caused by abnormally high IL-5 production.
|
27624222 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Decreased IL-5 production is the most likely explanation for the diminished airway eosinophilia observed.
|
11290768 |
2001 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Emerging data elucidating the pathogenesis of PPI-REE have shown that Th2-related inflammatory factors such as interleukin (IL)-13, IL-5, eotaxin-3 and major basic protein (MBP) are elevated in PPI-REE, similar to EoE.
|
26039722 |
2015 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Eosinophilic bronchitis is usually a Type 2 (T2)-driven process and therefore a sputum eosinophilia of greater than 3% usually indicates a response to treatment with corticosteroids or novel therapies directed against T2 cytokines such as IL-4, IL-5, and IL-13.
|
29018800 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Eosinophilic COPD may represent an overlap with asthma but the mechanism of eosinophilia is uncertain as, although an increase in sputum IL-5 has been detected, anti-IL-5 therapies are not effective in preventing exacerbations.
|
30834543 |
2019 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Exposure to mIL-17E resulted in a Th2-biased response, characterized by eosinophilia, increased serum IgE and IgG1, and a Th2 cytokine profile including elevated serum levels of IL-13 and IL-5 and elevated gene expression of IL-4, IL-5, IL-10, and IL-13 was observed in many tissues.
|
11714825 |
2001 |